Arch Therapeutics to Present at the SeeThruEquity Annual Innovations Investor Conference in Miami, Florida on Monday, February 22, 2016
(firmenpresse) - FRAMINGHAM, MA -- (Marketwired) -- 02/17/16 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, will present at the SeeThruEquity 2nd Annual Innovations Investor Conference at 1:00 PM EST on February 22, 2016.
Chief Executive Officer Terrence W. Norchi, MD will provide a corporate overview, including a near-term milestone update, and meet with investors. The conference will be held at The Ritz-Carlton South Beach in Miami, Florida.
The presentation will be webcast live and will be available for 90 days. To access the webcast, please . If you are a qualified investor or research analyst and wish to register to attend the Company''s presentation or to schedule a meeting at the conference, you may find information by clicking .
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch''s flagship development stage product candidate, known as AC5™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures. Find out more at .
Since the company''s founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered and undercovered microcap stocks and hosting investor conferences throughout the year. STE has been able to grow its research universe to over 176 names.
STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because it augments the conference experience with the firm''s research which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P Capital IQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4,500 attendees and have included over 1,700 1-on-1 meetings.
For more information please visit .
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at .
On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email:
Website:
Or
Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2308
Email:
Website:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.02.2016 - 06:57 Uhr
Sprache: Deutsch
News-ID 1415721
Anzahl Zeichen: 2332
contact information:
Contact person:
Town:
FRAMINGHAM, MA
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Arch Therapeutics to Present at the SeeThruEquity Annual Innovations Investor Conference in Miami, Florida on Monday, February 22, 2016
"
steht unter der journalistisch-redaktionellen Verantwortung von
Arch Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
